← ANALYST RATINGS · TIPRANKS
Dexcom (DXCM): analyst forecast and price target
Analyst consensus
Strong Buy19 Buy1 Hold0 Sell
Ratings of 20 analysts in the last 3 months12-month forecast
Based on 20 price targets given in the last 3 months, the average target is $96.39, the highest $115, the lowest $82.00. The average is +12.0% from the last price of $86.04.
Analyst ratings 26
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $105 | Buy | +22.0% | Reiterated | 14.10.26on TipRanks Oct 15 06:25 | −0.8%next day +4.8% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $90.00 | Buy | +4.6% | Reiterated | 14.10.26on TipRanks Oct 15 05:30 | −0.8%next day +4.8% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $95.00 → $100+5.3% | Buy | +16.2% | Assigned | 13.10.26on TipRanks 07:35 | −1.0%next day −0.8% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $90.00 → $96.00+6.7% | Buy | +11.6% | Reiterated | 12.10.26on TipRanks 08:35 | +2.2%next day −1.0% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $115 | Buy | +33.7% | Initiated | 07.10.26on TipRanks 03:55 | +1.3%next day +0.6% · 5 days 0.0% | ↗ |
| Shagun Singh Chadha★★★★★★★★★★#9557 · hits 48% · avg −0.4% | RBC Capital | $90.00 → $105+16.7% | Buy | +22.0% | Reiterated | 01.10.26on TipRanks 07:55 | −0.2%next day −1.7% · 5 days −3.4% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $102 | Buy | +18.5% | Reiterated | 23.09.26on TipRanks 22:25 | −0.2%next day −1.5% · 5 days −1.0% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $95.00 | Buy | +10.4% | Reiterated | 18.09.26on TipRanks 02:20 | +1.5%next day −1.8% · 5 days −4.3% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $97.00 → $95.00−2.1% | Buy | +10.4% | Reiterated | 14.09.26on TipRanks 20:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $94.00 → $91.00−3.2% | Hold | +5.8% | Downgrade | 14.09.26on TipRanks 20:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $94.00 | Buy | +9.3% | Reiterated | 14.09.26on TipRanks 20:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $92.00 → $90.00−2.2% | Hold | +4.6% | Reiterated | 14.09.26on TipRanks 20:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $96.00 → $95.00−1.0% | Buy | +10.4% | Reiterated | 14.09.26on TipRanks 20:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $97.00 → $94.00−3.1% | Buy | +9.3% | Reiterated | 14.09.26on TipRanks 20:05 | — | |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | $82.00 | Hold | −4.7% | Reiterated | 04.08.26on TipRanks Aug 5 08:08 | −2.2%next day −4.7% · 5 days +3.1% | ↗ |
| Steven Silver★★★★★★★★★★#2962 · hits 80% · avg +22.7% | Argus Research | $86.00 → $96.00+11.6% | Buy | +11.6% | Reiterated | 03.08.26on TipRanks Aug 4 09:26 | +3.2%next day −2.2% · 5 days −1.6% | ↗ |
| William Plovanic★★★★★★★★★★#5377 · hits 43% · avg +1.3% | Canaccord Genuity | $82.00 → $90.00+9.8% | Buy | +4.6% | Reiterated | 03.08.26on TipRanks 07:11 | +3.2%next day −2.2% · 5 days −1.6% | ↗ |
| Kieran Ryan | Deutsche Bank | $86.00 → $92.00+7.0% | Buy | +6.9% | Assigned | 31.07.26on TipRanks Aug 3 07:11 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | — | Buy | — | Reiterated | 31.07.26on TipRanks 12:22 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 31.07.26on TipRanks 10:12 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | $91.00 → $94.00+3.3% | Buy | +9.3% | Reiterated | 31.07.26on TipRanks 08:40 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Name not given | — | $85.00 → $90.00+5.9% | Buy | +4.6% | Reiterated | 31.07.26on TipRanks 08:20 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $77.00 → $82.00+6.5% | Buy | −4.7% | Reiterated | 31.07.26on TipRanks 08:20 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $90.00 → $95.00+5.6% | Buy | +10.4% | Assigned | 31.07.26on TipRanks 07:26 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $80.00 → $105+31.2% | Buy | +22.0% | Reiterated | 31.07.26on TipRanks 07:26 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% | Piper Sandler | $88.00 → $95.00+8.0% | Buy | +10.4% | Reiterated | 31.07.26on TipRanks 07:18 | +11.2%next day +3.2% · 5 days −2.0% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $96.00 | Buy | +11.6% | Reiterated | 28.07.26on TipRanks Jul 29 01:15 | +1.8%next day +1.9% · 5 days +12.0% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $80.00 | Buy | −7.0% | Reiterated | 15.05.26on TipRanks 13:30 | +7.8%next day +5.7% · 5 days +16.1% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $77.00 | Buy | −10.5% | Reiterated | 15.05.26on TipRanks 06:55 | +7.8%next day +5.7% · 5 days +16.1% | ↗ |
| Unknown Analyst | Jefferies | $112 | Buy | +30.2% | Reiterated | 14.05.26on TipRanks May 15 05:15 | −2.1%next day +7.8% · 5 days +25.1% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | — | Hold | — | Reiterated | 13.02.26on TipRanks 09:05 | +7.5%next day +0.4% · 5 days +4.5% | ↗ |
| Daniel Markowitz CFA★★★★★★★★★★#1752 · hits 61% · avg +22.3% | Evercore ISI | $68.00 | Hold | −21.0% | Initiated | 26.11.25on TipRanks Nov 25 06:45 | −1.8%next day +0.7% · 5 days +3.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Dexcom
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $94.65 at a price of $86.29 (+9.7%); now: $96.39 at $86.04 (+12.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 0 | 0 | 0 |
| Buy | 41 | 50 | 64 | 38 | 32 | 16 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 2 | 2 | 2 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 22.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.67 (from $0.63 to $0.70). Last quarter: $0.70.
Sales
Next quarter’s sales estimate — $1.3B (from $1.3B to $1.3B). Last quarter: $1.3B.
Best top-analyst consensus in the sector · Healthcare
About Dexcom
- CEO: Jacob Steven Leach
- Employees: 11,050
- 6340 Sequence Drive, San Diego, CA, 92121, US
- www.dexcom.com
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Data from the stock’s TipRanks forecast page, read 4 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗